MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$60,693K
Free Cash flow
$19,076K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Sales and maturities of marketab...
Accrued liabilities
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Accounts payable
Inventory
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-57,939
-94,391
-58,575
-229,709
Stock-based compensation expense
35,371
34,018
25,788
26,252
Depreciation and amortization expense
381
386
392
358
Inventory write-down
11,051
-
-
-
Amortization of debt issuance costs and discount
464
449
468
329
Amortization and interest accretion related to operating leases
-
408
1,548
1,551
Loss on extinguishment of debt
-
-
0
-2,779
Amortization of right-of-use assets
1,053
-
-
-
Other non-cash items, net
65
3,052
-
330
Trade receivables, net
4,955
52,880
21,191
34,054
Prepaid expenses and other assets
1,225
40,649
-1,525
-9,275
Inventory
11,462
22,187
1,729
5,820
Accounts payable
-21,136
3,584
4,942
5,961
Accrued liabilities
71,253
4,287
-88,419
187,537
Operating lease liability
21
-
-
-
Accrued interest, net of interest received on maturity of investments
925
1,980
2,403
202
Net cash used in operating activities
23,329
-167,435
-133,460
79,850
Purchases of marketable securities
148,850
157,829
212,956
478,208
Sales and maturities of marketable securities
187,298
353,869
240,146
275,069
Acquisition of intangible asset
-
-
0
3,000
Purchases of property and equipment
4,253
3,849
-390
857
Net cash provided by investing activities
34,195
192,191
27,580
-206,996
Proceeds from issuance or sale of equity-Nonrelated Party
-
-
0
0
Proceeds from issuance or sale of equity-Related Party
-
-
9,939
17,735
Proceeds from issuance of debt
-
-
0
350,000
Payment of debt issuance costs
-
-
983
9,424
Repayment of debt
-
-
0
121,664
Proceeds from exercise of common stock options
3,112
2,329
-
-
Net cash provided by financing activities
3,112
2,329
8,956
236,647
Effect of exchange rate changes on cash, cash equivalents and restricted cash
57
1,320
13
-
Net increase in cash, cash equivalents, and restricted cash
60,693
28,405
-96,911
109,501
Cash, cash equivalents, and restricted cash at beginning of period
300,694
300,694
-
105,019
Cash, cash equivalents, and restricted cash at end of period
292,881
232,188
-
300,694
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Sales and maturities
of marketable...
$187,298K
(-67.03%↓ Y/Y)
Accrued liabilities
$71,253K
(117.34%↑ Y/Y)
Proceeds from exercise of
common stock options
$3,112K
Stock-based compensation
expense
$35,371K
(-23.26%↓ Y/Y)
Inventory write-down
$11,051K
Amortization of right-of-use
assets
$1,053K
Accrued interest, net of
interest received on...
$925K
(-72.52%↓ Y/Y)
Amortization of debt issuance
costs and discount
$464K
(-42.50%↓ Y/Y)
Net cash provided by
investing activities
$34,195K
(-83.85%↓ Y/Y)
Net cash used in
operating activities
$23,329K
(117.16%↑ Y/Y)
Net cash provided by
financing activities
$3,112K
(-70.02%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$57K
Canceled cashflow
$153,103K
Canceled cashflow
$96,782K
Net increase in
cash, cash...
$60,693K
(-29.57%↓ Y/Y)
Purchases of marketable
securities
$148,850K
(-58.23%↓ Y/Y)
Purchases of property and
equipment
$4,253K
Net loss
-$57,939K
(49.84%↑ Y/Y)
Accounts payable
-$21,136K
(-275.82%↓ Y/Y)
Inventory
$11,462K
(-61.05%↓ Y/Y)
Trade receivables,
net
$4,955K
(-80.50%↓ Y/Y)
Prepaid expenses and
other assets
$1,225K
(-97.27%↓ Y/Y)
Other non-cash items,
net
$65K
(106.90%↑ Y/Y)
Buy us a coffee
MADRIGAL PHARMACEUTICALS, INC. (MDGL)
MADRIGAL PHARMACEUTICALS, INC. (MDGL)